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OA is a disease affecting the metabolism of all joint tissues
leading to structural changes visible by imaging techni-
ques. Unfortunately, features visible by imaging are in
most cases irreversible and progressively moving towards
worsening. One challenge for the next decade will be dis-
ease detection at the early stage when the first molecular/
metabolic changes appear in joint tissues. Another chal-
lenge is to develop tools to assess the efficacy of OA treat-
ment on the natural history of the disease. Therefore,
there is an acute need for reliable biological markers that
can facilitate earlier diagnosis of OA, predict the progres-
sion of the disease and evaluate the efficacy of therapeutic
modalities.
A recent literature review resulted in the identification
of 16 biochemical markers investigating cartilage matrix
turnover. Nine concerned collagen type II degradation
(Coll2-1, Coll2-1NO2, CTX-II, Helix-II, C2C, TIINE,
CIIM) and synthesis (PIIANP, PIICP). Keratan sulphate,
chondroitin sulphate 846 (CS846) and ARGS-aggrecan
fragment investigate proteoglycans degradation. Serum
cartilage oligomeric matrix protein (COMP), deamidated-
COMP (D-COMP), fibuline-3 fragments (Fib3-1 and
Fib3-2) were the other biochemical markers that are con-
sidered as markers of cartilage matrix metabolism.
Risedronate and strontium ranelate, two drugs currently
used to treat osteoporosis decreased urinary CTX-II levels
suggesting that they can modulate cartilage metabolism,
even if they did not alter radiological progression. How-
ever, recently, it was demonstrated that CTX-II was more
strongly associated with bone markers (i.e. uNTXI,
uCTXI, serum PINP, and osteocalcin) than with other car-
tilage markers (PIIANP, sCS846, sCOMP), while the
“other” cartilage markers were not so strongly associated
with the bone markers. These data indicate that CTX-II
might reflect bone rather than cartilage metabolism. In an
exploratory study investigating the effects of three intra-
articular injections of hyaluronic acid (Hylan GF-20) on
the evolution of 10 biochemical markers, we have demon-
strated that uCTXII, sColl2-1 and sColl2-1NO2 levels
were significantly affected by treatment suggesting that
these markers are sensitive to metabolic change occurring
in one single joint. More recently, we have observed that
three months treatment with bio-optimized curcumin
significantly decreased sColl2-1 level in 24 patients with
knee OA, suggesting that sColl2-1 could be a companion
marker to assess curcumin efficacy at an individual level
and in the next phases of its clinical development.
Although many OA-related biomarkers are currently
available they exist in various states of qualification and
validation. At this time, none of the existing biomarker
can be considered as a surrogate marker of clinical and
imaging feature for the diagnosis or prognosis of the dis-
ease. In this context, the recent development of large
cohort designed to qualify biomarker will accelerate bio-
chemical marker implementation in clinical research.
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